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One has only to compare the 1980 American College of
Cardiology (ACC) Annual Scientific Session program to the
1997 program in Anaheim to be amazed at the marked
increase in the number of scientific abstracts presented (400
compared with 2,138). Why, then, is there widespread concern
about the future of cardiovascular research in the United
States? (1–4).
Before addressing this question, it is important to distin-
guish among the various types of research that have emerged
since 1980. First is basic research, involving genetics and
molecular biology. Basic research was virtually absent from the
1980 meeting. This type of research receives the highest
funding priority from both the National Institutes of Health
(NIH) and the American Heart Association (AHA). Investi-
gators can be either MDs or PhDs, but the considerable extra
training required, beyond the usual training in clinical cardi-
ology, makes this an unlikely course for financially indebted
cardiovascular trainees to pursue.
The second category involves experimental animal studies,
which in 1980 was “basic” research. Such investigators must
now have a reasonable understanding of molecular biology, in
addition to physiology, and may be either a PhD or MD. Once
again, the extra training requirements for this type of research
are a disincentive for MDs. Whether any incentive exists to
enter either type of basic research is strongly influenced by the
closeness of the collaboration between the basic researchers
and the clinicians at the trainee’s institution.
Third is clinical research that involves human subjects and
human diseases and is virtually always conducted by MDs.
Clinical investigators study the epidemiology, pathogenesis of
disease and mechanisms of disease management. These studies
usually do not require large numbers of patients, but may incur
substantial hospital or outpatient costs. Traditionally, clinical
research has relied heavily on support from clinical revenues
donated by the clinical faculty in addition to outside grant
support. This type of research is one of the easiest starting
points for cardiovascular trainees interested in research.
Clinical research requires a thorough understanding of patho-
physiology and clinical manifestations of disease supported by a
background knowledge of molecular cardiology. In addition, the
clinical investigator is generally involved in direct patient care and
teaching. From this group, some individuals evolve into “master
clinicians” who are able to recognize new manifestations of
diseases and intuitively understand the value of new diagnostic
procedures or therapies. These are the investigators who bring
the questions from the bedside to the research laboratory and,
conversely, from the basic laboratory to the bedside. It is this type
of investigation for which funding and academic encouragement
has dramatically declined since 1980 (1,2).
Two new disciplines of research have emerged since 1980—
clinical trials and outcomes research. Clinical trials are cur-
rently the most glamorous form of cardiovascular research. In
fact, cardiovascular medicine leads all other fields in the
number and scope of its clinical trials. The researchers are
MDs (mostly those who formerly would have performed
clinical research). Clinical trials have been an extremely valu-
able addition to clinical research, but they do have limitations
that are not generally appreciated. Trials are often initiated
before the mechanism of action of the treatment is fully
understood, leading to an inappropriate cessation of research
into a promising therapy (e.g., flosequinan, vesnarinone). The
patient populations in clinical trials are usually heavily skewed
toward the least complex patients and often suffer from
referral bias. Thus, only a small percentage of clinical ques-
tions can be subjected to trials. Many trials are funded directly
by the medical industry, which may have a different agenda
than clinicians (5–7). Trials currently enjoy strong support
from both the NIH and industry. A worrisome trend is that
nonphysician entrepreneurs may steal this show, which could
further cloud the interpretation of trials (8).
Finally, there is outcomes research—arguably, this has
always been a goal of clinical research. Although outcomes
research can be prospective, it is commonly a retrospective,
observational analysis. It often deals with practical clinical
issues for the purpose of improving daily practice. This is a
form of research favored by managed care. Outcomes analyses
performed from large clinical databases have provided ex-
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tremely useful information, much of which cannot come from
trials (8). Indeed, the newly revised ACC Database will be such
an instrument (see the report by Weintraub et al. in this issue
of the Journal). Outcomes research will be more common in
the future; therefore, cardiovascular specialists must be more
involved with it to ensure that the data are properly analyzed.
Outcomes research is funded by government, industry and
managed care.
In summary, the era since 1980 has seen remarkable growth
in the size and diversity of cardiovascular research. However,
support for classic clinical research has steadily and somewhat
quietly eroded; so now, unfortunately, it is not a career readily
chosen by current trainees. The clinical research role models are
being forced to spend more and more time in clinical care, with
little time for contemplating and brainstorming. They have little
prospect of national or local research funding. At a time when
basic research has provided a “gold mine” for clinical research, it
is being eschewed by the next generation of researchers (1).
The result of the trend away from clinical research is shown
in Figure 1. This figure compares the number of abstracts
submitted to and accepted by the ACC Annual Scientific
Sessions since 1992 (in thousands). By the very nature of our
meeting, most abstracts submitted represent clinical rather
than basic research. It is clear that the number of abstracts
submitted and accepted from the United States has plateaued
(and actually declined for 1997), whereas the number from
outside the United States has steadily increased (from a base
of ,5% in 1980). The steadily increasing number of submis-
sions from international clinical research has, in a sense,
“covered up” the lack of growth in output from the United States.
Is this merely the expected result of progress? Has classic
clinical research told us all we need to know about the
mechanisms of cardiovascular disease? Is clinical research too
inefficient to be conducted in all American medical schools?
Should there only be a few research schools, while the remain-
ing schools concentrate only on medical education? (9)
Personally, I reject these notions. As pointed out recently,
this would be a regression to the pre-Flexnerian Era (1).
Nonresearch schools would become analogous to medieval
monasteries, simply passing on what is known but not creating
new knowledge. For clinical teachers to be exciting (and
up-to-date), they must be in a milieu where clinical research is
being performed and new concepts are being discussed. Med-
ical school diversity and research support for young investiga-
tors have been the great strengths of the American research
system, and this would be lost if research were confined to only
a few institutions (1).
Managed care has derived more direct benefit from clinical
research than from basic research but up to now has not been
willing to pay for it (4). There has been a 30% reduction in
clinical income because of reduced payments for clinical care
from both managed care and Medicare. This has significantly
reduced the nearly 1 billion dollars that clinical faculty had
voluntarily relinquished to support clinical research (11).
Likewise, universities do not support clinical research,
because, as I noted in an earlier President’s Page, post-MD
education and research are not formal university disciplines
(10). The NIH does not give high priority to clinical research,
except for clinical trials (although there is currently an NIH
panel that will advise the director of the NIH on problems
facing clinical research). The AHA has also turned toward
more basic research in its local and national funding, thus
reducing opportunities for young clinical investigators. Indus-
try supports clinical research; but, overall, this is only 10% of
the size of NIH support, and industry-sponsored research has
become more targeted and is usually not investigator initiated.
If we are to continue to serve our patients by advancing our
ability to diagnose and treat cardiovascular disease, it is time
for us to point out the threat to the development of new
knowledge (12). I have appointed a College task force to
develop a position statement on the role of clinical research in
the advancement of cardiovascular medicine. As our strategic
planning process unfolds this year, this issue will be explored.
Two possibilities that immediately come to mind are for the
College to establish clinical investigator awards and to convene
a meeting of academia, industry and government to discuss
solutions to this problem.
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Figure 1. Abstracts at the ACC annual scientific sessions.
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